Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Bcl-2–associated athanogene 3 protects the heart from ischemia/reperfusion injury
Feifei Su, Valerie D. Myers, Tijana Knezevic, JuFang Wang, Erhe Gao, Muniswamy Madesh, Farzaneh G. Tahrir, Manish K. Gupta, Jennifer Gordon, Joseph Rabinowitz, Frederick V. Ramsey, Douglas G. Tilley, Kamel Khalili, Joseph Y. Cheung, Arthur M. Feldman
Feifei Su, Valerie D. Myers, Tijana Knezevic, JuFang Wang, Erhe Gao, Muniswamy Madesh, Farzaneh G. Tahrir, Manish K. Gupta, Jennifer Gordon, Joseph Rabinowitz, Frederick V. Ramsey, Douglas G. Tilley, Kamel Khalili, Joseph Y. Cheung, Arthur M. Feldman
View: Text | PDF
Research Article Cardiology Cell biology

Bcl-2–associated athanogene 3 protects the heart from ischemia/reperfusion injury

  • Text
  • PDF
Abstract

Bcl-2–associated athanogene 3 (BAG3) is an evolutionarily conserved protein expressed at high levels in the heart and the vasculature and in many cancers. While altered BAG3 expression has been associated with cardiac dysfunction, its role in ischemia/reperfusion (I/R) is unknown. To test the hypothesis that BAG3 protects the heart from reperfusion injury, in vivo cardiac function was measured in hearts infected with either recombinant adeno-associated virus serotype 9–expressing (rAAV9-expressing) BAG3 or GFP and subjected to I/R. To elucidate molecular mechanisms by which BAG3 protects against I/R injury, neonatal mouse ventricular cardiomyocytes (NMVCs) in which BAG3 levels were modified by adenovirus expressing (Ad-expressing) BAG3 or siBAG3 were exposed to hypoxia/reoxygenation (H/R). H/R significantly reduced NMVC BAG3 levels, which were associated with enhanced expression of apoptosis markers, decreased expression of autophagy markers, and reduced autophagy flux. The deleterious effects of H/R on apoptosis and autophagy were recapitulated by knockdown of BAG3 with Ad-siBAG3 and were rescued by Ad-BAG3. In vivo, treatment of mice with rAAV9-BAG3 prior to I/R significantly decreased infarct size and improved left ventricular function when compared with mice receiving rAAV9-GFP and improved markers of autophagy and apoptosis. These findings suggest that BAG3 may provide a therapeutic target in patients undergoing reperfusion after myocardial infarction.

Authors

Feifei Su, Valerie D. Myers, Tijana Knezevic, JuFang Wang, Erhe Gao, Muniswamy Madesh, Farzaneh G. Tahrir, Manish K. Gupta, Jennifer Gordon, Joseph Rabinowitz, Frederick V. Ramsey, Douglas G. Tilley, Kamel Khalili, Joseph Y. Cheung, Arthur M. Feldman

×

Figure 5

BAG3 translocates to the nucleus in neonatal mouse ventricular cardiomyocytes following hypoxia/reoxygenation or BAG3 knockdown.

Options: View larger image (or click on image) Download as PowerPoint
BAG3 translocates to the nucleus in neonatal mouse ventricular cardiomyo...
To determine whether BAG3 translocated to the nucleus during hypoxia/reoxygenation (H/R), neonatal mouse ventricular cardiomyocytes (NMVCs) were exposed to H/R (5% CO2 and 95% nitrogen at 3 l/min in the absence of glucose for 14 hours at 37°C followed by reoxygenated for 4 hours with 5% CO2 and 95% humidified air in medium containing glucose) or normoxic conditions and infected with an adenovirus encapsulated with a siRNA (Ad-siBAG3) to decreased BAG3 levels or with an adenovirus encapsulated with GFP (Ad-GFP control). Three independent cultures of NMVCs were used in each experiment in order to have n = 3 for each intervention. NMVCs were fixed and stained with a BAG3 antibody, an α-actinin antibody, or the nuclear counter-stain DAPI. (A) Representative confocal images of BAG3 localization in NMVCs that were positive for DAPI and α-actinin. Scale bars: 10 μM. Both H/R and BAG3 knockdown with Ad-siBAG3 appear to increase the presence of BAG3 in the nucleus when compared with NMVCs treated under control conditions. (B) To confirm the visual observation that BAG3 translocated to the nucleus during the stress of H/R or after knockdown with siBAG3, cytoplasm and nuclear fractions of NMVCs were prepared using a NE-PER nuclear and cytoplasmic extraction kit (ThermoFisher Scientific). Western blot of BAG3 in cytoplasmic and nuclear fractions obtained from Ad-GFP and BAG3 knockdown (Ad-siBAG3) NMVCs subjected to normoxic (control) or H/R incubations demonstrates that β-tubulin was present in all 3 cytosol fractions but not in the nuclear fraction, whereas histone was present in all 3 nuclear fractions but not in the cytosol, suggesting adequate separation of the two fractions. (C) Quantification of Western blots of nuclear extracts demonstrates that BAG3 levels (normalized to histone) in nuclear extracts increased following BAG3 knockdown (Ad-siBAG3) or after H/R. Two-way ANOVA with Bonferroni multiple comparison adjustments were used to assess differences across the 4 investigational groups.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts